Full Text
Why are the findings of cost-effectiveness analyses of biologic treatment for rheumatoid arthritis so different?

Abstract

Authors

E. Druyts K. Thorlund E. Mills

Back to Volume 16, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×